关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
1 ~: C. k; f! ^) `    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
& v, b  c; K4 K; i4 O6 c, W3 Z: ~
作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
; l% ?; s5 W# D$ O5 o. a& C( i$ c, dDear Group,

+ k4 R+ x4 U$ M( e$ G9 E' f, ZSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
* |. r% h! Z; qtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
9 ?+ {) ~- V+ h! Jremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
" I/ ^& c) h, n6 B# j( zdoes spike up the immune system so I hope more reports come out on this issue.
9 C1 j# X# ]5 @. `
2 P. X+ m# V, |The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
+ L5 L8 ]9 g+ odifferent from the stopping Gleevec trial in France which only targets patients
/ L+ P, G! T( Q7 w% z' b  ?who have done well on Gleevec.
- \1 {: s+ ]# ]$ R
2 ~+ u  s, h! V3 AHopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.
( }* F1 M4 f* d
Best Wishes,
7 ~4 i2 c" J/ H. vAnjana
6 i  w( ?. n6 o( e
, M+ [' H4 H  x! X  ?. T/ S8 ?
9 T, L% U) @. I! L3 y5 t  E4 L
4 t9 p- N8 L5 f8 dHaematologica. 2011 Aug 9. [Epub ahead of print]
( a$ J; ]" q" O8 C4 W1 f, tDurable complete molecular remission of chronic myeloid leukemia following
! }4 X# N5 d; ^0 Xdasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
# x! }& L/ s/ _3 G" RSource
Adelaide, Australia;
1 d2 ?7 @2 \; U
$ j. s; m  a- l9 r% ]Abstract
8 K$ G2 W! u$ G0 s2 GPatients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
4 \! [+ B' G- m' o; k! [treatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
5 f3 E, ^, H$ dtreatment following imatinib failure. Two of the three patients remain in
% M; J* b  H) Ccomplete molecular response more than 12 months after stopping dasatinib. In
6 n5 C& J) c- q5 J5 l6 t2 Y) ythese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
" S* m2 [- ^8 ~4 `1 o/ `& y# Fimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
- B/ H# ?/ ~$ X! y# b$ ythe emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
7 K, N* h; r6 D) _, ?, {- u7 |* Ucharacteristics of complete molecular response on dasatinib treatment may be
- H- f+ Z9 Y' h" ~1 s, @* R; ]similar to that achieved with imatinib, at least in patients with adverse
' p) p- k1 }4 Tdisease features.
. i) g# `) L. Q7 d

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
# j4 ]% `9 n' B% V& e
# l( y" C0 D0 K# V! F作者：来自法国STIM试验
& q, k: I8 [9 X# [7 X5 W来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事